Skip to content
The Nexus
DossierENTITY

Skyrizi

Coverage of Skyrizi in the Nexus archive.

Earliest in view: Jun 29 · 16:53 UTCMost recent: Jun 29 · 16:53 UTC
Co-mentioned in this coverage
FDAorganization1AbbVieorganization1risankizumabtopic1plaque psoriasistopic1psoriatic arthritistopic1children 6 years and oldertopic1
Recent coverage
  • HEALTHJun 29 · 16:53 UTCMEDPAGE TODAY
    FDA Expands Risankizumab Label in Psoriatic Disease

    The FDA expanded the indications for risankizumab (Skyrizi) in plaque psoriasis and psoriatic arthritis to include treatment of children 6 years and older. AbbVie announced this update, noting risankizumab is an interleukin (IL)-23 antagonist.